ASBP
NASDAQ · Pharmaceuticals
Aspire Biopharma Holdings In
$1.04
+0.24 (+29.51%)
Financial Highlights (FY 2025)
Revenue
2.20M
Net Income
266.8K
Gross Margin
63.6%
Profit Margin
12.1%
Rev Growth
+5.7%
D/E Ratio
0.42
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 63.6% | 63.6% | 63.6% |
| Operating Margin | 15.9% | 17.9% | 17.2% |
| Profit Margin | 12.1% | 14.9% | 13.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.20M | 2.09M | 2.38M |
| Gross Profit | 1.40M | 1.33M | 1.51M |
| Operating Income | 350.5K | 374.4K | 410.4K |
| Net Income | 266.8K | 312.0K | 325.1K |
| Gross Margin | 63.6% | 63.6% | 63.6% |
| Operating Margin | 15.9% | 17.9% | 17.2% |
| Profit Margin | 12.1% | 14.9% | 13.7% |
| Rev Growth | +5.7% | +22.2% | +15.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 703.8K | 744.6K | 770.5K |
| Total Equity | 1.66M | 1.82M | 1.58M |
| D/E Ratio | 0.42 | 0.41 | 0.49 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 501.0K | 520.7K | 532.7K |
| Free Cash Flow | 197.3K | 259.9K | 336.6K |